2021
Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer
Doyle HA, Gee RJ, Masters TD, Gee CR, Booth CJ, Peterson-Roth E, Koski RA, Helfand SC, Price L, Bascombe D, Jackson D, Ho R, Post GR, Mamula MJ. Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer. Translational Oncology 2021, 14: 101205. PMID: 34419682, PMCID: PMC8379704, DOI: 10.1016/j.tranon.2021.101205.Peer-Reviewed Original ResearchEpidermal growth factor receptorAnti-tumor immunityMonoclonal antibody therapyEGFR/HER2Antibody therapyPhase I/II open label studyCanine cancersHuman epidermal growth factor receptorImmune modifying therapiesOpen-label studyCD8 T cellsHuman cancersStandard cancer therapiesProgression of diseaseInhibited tumor growthSpontaneous canine cancersGrowth factor receptorMonoclonal therapyCheckpoint inhibitorsModifying therapiesIgG depositionObjective responseVaccine therapyMetastatic sitesAntigen response
2020
Persistent STAG2 mutation despite multimodal therapy in recurrent pediatric glioblastoma
Hong CS, Vasquez JC, Kundishora AJ, Elsamadicy AA, Beckta JM, Sule A, Marks AM, Leelatian N, Huttner A, Bindra RS, DiLuna ML, Kahle KT, Erson-Omay EZ. Persistent STAG2 mutation despite multimodal therapy in recurrent pediatric glioblastoma. Npj Genomic Medicine 2020, 5: 23. PMID: 32528726, PMCID: PMC7264170, DOI: 10.1038/s41525-020-0130-7.Peer-Reviewed Original ResearchPediatric patientsStandard chemoradiationSTAG2 mutationsTumor clonesPediatric glioblastomaGross total resectionMultiple surgical resectionsTime of recurrenceHigh-grade gliomasDNA damage repair defectsWhole-exome sequencingVariety of treatmentsSurgical resectionNovel deleterious mutationsStandard therapyTotal resectionVaccine therapyClinical evidencePreclinical dataTreatment optionsMultimodal therapyPreclinical studiesClinical settingTherapyAdult counterparts
2016
Evolving Immunotherapy Approaches for Renal Cell Carcinoma
Curtis SA, Cohen JV, Kluger HM. Evolving Immunotherapy Approaches for Renal Cell Carcinoma. Current Oncology Reports 2016, 18: 57. PMID: 27475806, DOI: 10.1007/s11912-016-0542-9.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaMetastatic renal cell carcinomaCell carcinomaImmune therapy approachesCheckpoint inhibitorsCytokine therapyCytotoxic chemotherapyOverall survivalImmunotherapy approachesVaccine therapyImmune therapyImmune systemTherapyCell therapyCarcinomaTherapy approachesHigh rateSurvivalMorbidityChemotherapyMortality
2014
Update on Vaccines for High-Risk Melanoma
Weiss SA, Chandra S, Pavlick AC. Update on Vaccines for High-Risk Melanoma. Current Treatment Options In Oncology 2014, 15: 269-280. PMID: 24788575, DOI: 10.1007/s11864-014-0283-7.Peer-Reviewed Original ResearchConceptsHigh-risk melanomaRole of vaccinesClinical trialsCytotoxic T-lymphocyte antigen-4Death-1 monoclonal antibodyT-lymphocyte antigen-4Cell death-1 monoclonal antibodyImmunogenic solid tumorsOpinion statementThe managementPrimary surgical resectionHigh-risk diseaseMeaningful clinical responsesGranulocyte-macrophage colony-stimulating factorImmune stimulatory agentsDevelopment of vaccinesMacrophage colony-stimulating factorColony-stimulating factorAdjuvant settingImmunomodulatory therapyAdjuvant optionClinical responseMelanoma vaccineSurgical resectionVaccine therapyClinical outcomes
2012
Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy
Yeung JT, Hamilton RL, Okada H, Jakacki RI, Pollack IF. Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy. Journal Of Neuro-Oncology 2012, 111: 103-111. PMID: 23179498, PMCID: PMC3546121, DOI: 10.1007/s11060-012-0998-x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedAged, 80 and overAntigens, NeoplasmBrainBrain NeoplasmsCancer VaccinesChildChild, PreschoolEpendymomaFemaleGene Expression Regulation, NeoplasticHistocompatibility Antigens Class IHumansInfantInhibitor of Apoptosis ProteinsInterleukin-13 Receptor alpha1 SubunitMaleMiddle AgedReceptor, EphA2SurvivinWT1 ProteinsConceptsTumor-associated antigensMore tumor-associated antigensIL-13Rα2Positive stainingAdult ependymomasMultiple peptides vaccineNormal brain tissueGlioma vaccinesImmunotherapy approachesVaccine therapyPediatric casesAdult casesTumor recurrenceClinical trialsPeptide vaccinePediatric ependymomaNormal brainEpendymomaBrain tissuePediatric gliomasTumor 1SurvivinStainingEphA2Vaccine
2004
Immunotherapy--perspectives in therapy of ovarian carcinomas.
Zapletalová K, Tobiasová Z, Spísek R, Rob L, Bartůnková J. Immunotherapy--perspectives in therapy of ovarian carcinomas. Česká Gynekologie 2004, 69: 372-5. PMID: 15587893.Peer-Reviewed Original ResearchConceptsUniversity Hospital MotolMonoclonal antibody therapyCytokine therapyAntibody therapyMalignant ovarian epithelial tumorsCombination of surgeryDepartment of GynecologyOvarian cancer patientsOvarian epithelial tumorsDendritic cellsVaccine therapyMedical FacultyCancer patientsIL-2Clinical studiesTherapeutic protocolsEpithelial tumorsTherapyGM-CSFImmunotherapyTumor cellsMotolChemotherapySurgeryUsual standard
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply